Skip to main content
    P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $130.95
    -3.43 (-2.55%)

    Market Cap: $8.55B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Protagonist Therapeutics Inc (PTGX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Protagonist Therapeutics (PTGX) trades at 27.7x trailing earnings and 15.8x sales. Its P/S of 15.8x is below its 5-year median of 17.3x. Its forward P/E is 36.9x. The median P/E across 3 similar companies is 66.5x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 24.9% lower over the next year. Its free cash flow yield is 1.3%.

    MultipleValue
    P/E (trailing)27.7x
    Forward P/E36.9x
    Price to sales15.8x
    Price to book8.0x
    EV/EBITDA25.6x
    Price to FCF79.6x
    EV/FCF75.1x
    PEGN/A
    FCF yield1.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 110.5% above 3.8x.

    MultipleCurrent5-year median10-year median
    P/S15.8x17.3xN/A
    P/B8.0x4.5x3.8x
    Medians of month-end values through Oct 2026: 51 to 60 months (5-year) and 111 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 4.7x in 2018 to 120.0x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$87.34N/A120.0x9.0x
    2024$38.609.2x5.6x3.8x
    2023$22.93N/A23.6x4.2x
    2022$10.91N/A20.0x2.5x
    2021$34.20N/A58.6x5.5x
    2020$20.16N/A24.7x2.9x
    2019$7.05N/AN/A2.4x
    2018$6.73N/A4.7xN/A
    2017$20.80N/A19.3xN/A
    2016$21.99N/AN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PTGX

    What is PTGX's forward P/E ratio?

    Protagonist Therapeutics has a forward P/E ratio of 36.9x.

    Is PTGX stock overvalued?

    GNG's valuation label for PTGX is Overvalued. Its P/E of 27.7x compares with a median of 66.5x across 3 similar companies.

    What is PTGX's price to sales ratio?

    Protagonist Therapeutics has a price to sales ratio of 15.8x.